{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:43:05Z","timestamp":1789494185846,"version":"build-2803163510"},"reference-count":147,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00204-024-03765-8","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T14:01:58Z","timestamp":1715695318000},"page":"2409-2427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns"],"prefix":"10.1007","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-4865","authenticated-orcid":false,"given":"Brian A.","family":"Baldo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"key":"3765_CR1","unstructured":"ACMD (Advisory Council on the Misuse of Drugs). MDMA (\u2018ecstasy\u2019): A review of its harms and classification under the Misuse of Drugs Act 1971 (Nutt DJ, 2008) https:\/\/assets.publishing.service.gov.uk\/media\/5a7ad072e5274a34770e74e6\/mdma-report.pdf (Accessed Oct 20, 2023)"},{"issue":"8","key":"3765_CR2","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/j.1553-2712.1998.tb02512.x","volume":"5","author":"I Ajaelo","year":"1998","unstructured":"Ajaelo I, Koenig K, Snoey E (1998) Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 5(8):839\u2013840. https:\/\/doi.org\/10.1111\/j.1553-2712.1998.tb02512.x","journal-title":"Acad Emerg Med"},{"key":"3765_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/hup.2607","author":"S Assi","year":"2017","unstructured":"Assi S, Gulyamova N, Ibrahim K, Kneller P, Osselton D (2017) Profile, effects, and toxicity of novel psychoactive substances: a systematic review of quantitative studies. Hum Psychopharmacol. https:\/\/doi.org\/10.1002\/hup.2607","journal-title":"Hum Psychopharmacol"},{"key":"3765_CR4","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1007\/s00204-018-2244-6","volume":"92","author":"BA Baldo","year":"2018","unstructured":"Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92:2457\u20132473. https:\/\/doi.org\/10.1007\/s00204-018-2244-6","journal-title":"Arch Toxicol"},{"key":"3765_CR5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s44254-023-00018-2","volume":"1","author":"BA Baldo","year":"2023","unstructured":"Baldo BA (2023) Allergic and other adverse reactions to drugs used in anesthesia and surgery. Anaesthesiol Perioper Sci 1:16. https:\/\/doi.org\/10.1007\/s44254-023-00018-2","journal-title":"Anaesthesiol Perioper Sci"},{"key":"3765_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-51740-3","volume-title":"Drug allergy: clinical aspects, diagnosis, mechanisms structure-activity relationships","author":"BA Baldo","year":"2021","unstructured":"Baldo BA, Pham NH (2021) Drug allergy: clinical aspects, diagnosis, mechanisms structure-activity relationships, 2nd edn. Springer Nature, Cham, Switzerland. https:\/\/doi.org\/10.1007\/978-3-030-51740-3","edition":"2"},{"issue":"4","key":"3765_CR7","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s00213-005-0038-z","volume":"181","author":"KT Ball","year":"2005","unstructured":"Ball KT, Rebec GV (2005) Role of 5-HT2A and 5-HT2C\/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology 181(4):676\u2013687. https:\/\/doi.org\/10.1007\/s00213-005-0038-z","journal-title":"Psychopharmacology"},{"issue":"2","key":"3765_CR8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.brainres.2003.09.037","volume":"994","author":"KT Ball","year":"2003","unstructured":"Ball KT, Budreau D, Rebec GV (2003) Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res 994(2):203\u2013215. https:\/\/doi.org\/10.1016\/j.brainres.2003.09.037","journal-title":"Brain Res"},{"issue":"1\u20132","key":"3765_CR9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0014-2999(88)90056-8","volume":"149","author":"G Battaglia","year":"1998","unstructured":"Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1998) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149(1\u20132):159\u2013163. https:\/\/doi.org\/10.1016\/0014-2999(88)90056-8","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"3765_CR10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2045125314559539","volume":"5","author":"D Baumeister","year":"2015","unstructured":"Baumeister D, Tojo LM, Tracy DK (2015) Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol 5(2):97\u2013132. https:\/\/doi.org\/10.1177\/2045125314559539","journal-title":"Ther Adv Psychopharmacol"},{"issue":"4\u20135","key":"3765_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/s0197-0186(03)00027-5","volume":"43","author":"IL Bogen","year":"2003","unstructured":"Bogen IL, Haug KH, Myhre O, Fonnum F (2003) Short- and long-term effects of MDMA (\u201cecstasy\u201d) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43(4\u20135):393\u2013400. https:\/\/doi.org\/10.1016\/s0197-0186(03)00027-5","journal-title":"Neurochem Int"},{"key":"3765_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.pbb.2013.07.002","volume":"119","author":"JH Broadbear","year":"2014","unstructured":"Broadbear JH, Kabel D, Tracy L, Mak P (2014) Oxytocinergic regulation of endogenous as well as drug-induced mood. Pharmacol Biochem Behav 119:61\u201371. https:\/\/doi.org\/10.1016\/j.pbb.2013.07.002","journal-title":"Pharmacol Biochem Behav"},{"key":"3765_CR13","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1001\/jama.1987.03400060056021","volume":"258","author":"C Brown","year":"1987","unstructured":"Brown C, Osterloh J (1987) Multiple severe complications from recreational ingestion of MDMA (Ecstasy\u2019). JAMA 258:780\u2013781","journal-title":"JAMA"},{"issue":"348","key":"3765_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1626","volume":"19","author":"NA Buckley","year":"2014","unstructured":"Buckley NA, Dawson AH, Isbister GK (2014) Serotonin syndrome. BMJ 19(348):g1626. https:\/\/doi.org\/10.1136\/bmj.g1626","journal-title":"BMJ"},{"issue":"4","key":"3765_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1097\/00004714-200008000-00010","volume":"20","author":"J Cami","year":"2000","unstructured":"Cami J, Farr\u00e9 M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): psychomotor performance and subjective effects. J Clin Psychopharmacol 20(4):455\u2013466. https:\/\/doi.org\/10.1097\/00004714-200008000-00010","journal-title":"J Clin Psychopharmacol"},{"key":"3765_CR16","first-page":"61","volume":"85","author":"NTA Campkin","year":"1992","unstructured":"Campkin NTA, Davies UM (1992) Another death from ecstasy. J R Soc Med 85:61","journal-title":"J R Soc Med"},{"key":"3765_CR17","unstructured":"CFSRE NPS Discovery. Available at https:\/\/www.cfsre.org\/images\/trendreports\/yir-2021\/YearInReview-2021.pdf. (Accessed Aug 15, 2023)"},{"key":"3765_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1177\/0269881113495119","volume":"27","author":"H Chabrol","year":"2013","unstructured":"Chabrol H, Oehen P (2013) MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder. J Psychopharmacol 27:865\u2013866. https:\/\/doi.org\/10.1177\/0269881113495119","journal-title":"J Psychopharmacol"},{"key":"3765_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/014107689108400622","volume":"84","author":"IS Chadwick","year":"1991","unstructured":"Chadwick IS, Linsley A, Freemont AJ et al (1991) Ecstasy, 3\u20134 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 84:371. https:\/\/doi.org\/10.1177\/014107689108400622","journal-title":"J R Soc Med"},{"key":"3765_CR20","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1038\/s41598-021-85389-x","volume":"11","author":"IV Cohen","year":"2021","unstructured":"Cohen IV, Makunts T, Abagyan RT, K, (2021) Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep 11:5997. https:\/\/doi.org\/10.1038\/s41598-021-85389-x","journal-title":"Sci Rep"},{"key":"3765_CR21","unstructured":"Consumption ecstasy in Australia (2023) Available at https:\/\/ndarc.med.unsw.edu.au\/news\/major-changes-australian-drug-use-during-2021-says-annual-drug-trends-reports. (Accessed Novemb 30 2023)"},{"key":"3765_CR22","unstructured":"Consumption ecstasy in Europe (2023) Available at https:\/\/www.emcdda.europa.eu\/publications\/european-drug-report\/2023\/mdma_en (Accessed Novemb 30 2023)"},{"key":"3765_CR23","unstructured":"Consumption ecstasy in US (2023) Available at https:\/\/nida.nih.gov\/publications\/research-reports\/mdma-ecstasy-abuse\/what-is-the-scope-of-mdma-use-in-the-united-states (Accessed Novemb 30 2023)"},{"key":"3765_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113894","volume":"347","author":"G Costa","year":"2022","unstructured":"Costa G, Golembiowska K (2022) Neurotoxicity of MDMA: main effects and mechanisms. Exp Neurol 347:113894. https:\/\/doi.org\/10.1016\/j.expneurol.2021.113894","journal-title":"Exp Neurol"},{"issue":"10","key":"3765_CR25","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1111\/j.1360-0443.2009.02649.x","volume":"104","author":"LB Cottler","year":"2009","unstructured":"Cottler LB, Leung KS, Abdallah AB (2009) Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study. Addict Abingdon Engl 104(10):1679\u20131690. https:\/\/doi.org\/10.1111\/j.1360-0443.2009.02649.x","journal-title":"Addict Abingdon Engl"},{"key":"3765_CR26","unstructured":"Council decision European Union (2005) Council decision 2005\/387\/JHA of 20 May 2005 on the information exchange, risk assessment and control of new psychoactive substances. Off J Eur Union L 127\/32"},{"key":"3765_CR27","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.1007\/s00213-018-5010-9","volume":"235","author":"AL Danforth","year":"2018","unstructured":"Danforth AL, Grob CS, Struble C et al (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology 235:3137\u20133148. https:\/\/doi.org\/10.1007\/s00213-018-5010-9","journal-title":"Psychopharmacology"},{"key":"3765_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/2050324517711069","author":"AK Davis","year":"2017","unstructured":"Davis AK, Rosenberg H (2017) Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine\/ ecstasy users in the United States and the United Kingdom. Drug Sci Policy Law. https:\/\/doi.org\/10.1177\/2050324517711069","journal-title":"Drug Sci Policy Law"},{"key":"3765_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1002\/(SICI)1099-1077(199705\/06)12:3<221::AID-HUP854>3.0.CO;2-C","volume":"12","author":"D Davison","year":"1997","unstructured":"Davison D, Parrott AC (1997) Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:221\u2013226. https:\/\/doi.org\/10.1002\/(SICI)1099-1077(199705\/06)12:3%3c221::AID-HUP854%3e3.0.CO;2-C","journal-title":"Hum Psychopharmacol"},{"issue":"2","key":"3765_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/00007691-200404000-00009","volume":"26","author":"R de la Torre","year":"2004","unstructured":"de la Torre R, Farr\u00e9 M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Cam\u00ed J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26(2):137\u2013144. https:\/\/doi.org\/10.1097\/00007691-200404000-00009","journal-title":"Ther Drug Monit"},{"issue":"3","key":"3765_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fgene.2012.00235","volume":"12","author":"R de la Torre","year":"2012","unstructured":"de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farr\u00e9 M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet 12(3):235. https:\/\/doi.org\/10.3389\/fgene.2012.00235","journal-title":"Front Genet"},{"issue":"1","key":"3765_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2009.09.009","volume":"107","author":"L Degenhardt","year":"2010","unstructured":"Degenhardt L, Bruno R, Topp L (2010) Is ecstasy a drug of dependence? Drug Alcohol Depend 107(1):1\u201310. https:\/\/doi.org\/10.1016\/j.drugalcdep.2009.09.009","journal-title":"Drug Alcohol Depend"},{"key":"3765_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/bjaed\/mkw068","volume":"17","author":"G Dignam","year":"2017","unstructured":"Dignam G, Bigham C (2017) Novel psychoactive substances: a practical approach to dealing with toxicity from legal highs. BJA Educ 17:172\u2013177. https:\/\/doi.org\/10.1093\/bjaed\/mkw068","journal-title":"BJA Educ"},{"issue":"12","key":"3765_CR34","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.257.12.1615","volume":"257","author":"GP Dowling","year":"1987","unstructured":"Dowling GP, McDonough ET 3rd, Bost RO (1987) A report of five deaths associated with the use of MDEA and MDMA. JAMA 257(12):1615\u20131617. https:\/\/doi.org\/10.1001\/jama.257.12.1615","journal-title":"JAMA"},{"issue":"4","key":"3765_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/02791072.1986.10472366","volume":"18","author":"J Downing","year":"1986","unstructured":"Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18(4):335\u2013340. https:\/\/doi.org\/10.1080\/02791072.1986.10472366","journal-title":"J Psychoactive Drugs"},{"issue":"9","key":"3765_CR36","doi-asserted-by":"publisher","first-page":"899","DOI":"10.3109\/15563650.2013.847187","volume":"51","author":"C Eiden","year":"2013","unstructured":"Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H (2013) Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol (phila) 51(9):899\u2013903. https:\/\/doi.org\/10.3109\/15563650.2013.847187","journal-title":"Clin Toxicol (phila)"},{"key":"3765_CR37","unstructured":"EMCDDA (2023) New psychoactive substances: health and social responses. Available from https:\/\/www.emcdda.europa.eu\/publications\/mini-guides\/new-psychoactive-substances-health-and-social-responses_en (Accessed 30 Oct 2023)"},{"issue":"3","key":"3765_CR38","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1213\/ANE.0000000000006303","volume":"137","author":"TD Emerick","year":"2023","unstructured":"Emerick TD, Martin TJ, Ririe DG (2023) Perioperative considerations for patients exposed to psychostimulants. Anesth Analg 137(3):474\u2013487. https:\/\/doi.org\/10.1213\/ANE.0000000000006303","journal-title":"Anesth Analg"},{"key":"3765_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1749-6632.2002.tb04181.x","volume":"965","author":"JK Fallon","year":"2002","unstructured":"Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965:399\u2013409. https:\/\/doi.org\/10.1111\/j.1749-6632.2002.tb04181.x","journal-title":"Ann N Y Acad Sci"},{"key":"3765_CR40","doi-asserted-by":"publisher","first-page":"650","DOI":"10.3389\/fpsyt.2019.00650","volume":"10","author":"AA Feduccia","year":"2019","unstructured":"Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (2019) Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry 10:650. https:\/\/doi.org\/10.3389\/fpsyt.2019.00650","journal-title":"Front Psychiatry"},{"issue":"2","key":"3765_CR41","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/0014-2999(90)94150-v","volume":"191","author":"JL Fitzgerald","year":"1990","unstructured":"Fitzgerald JL, Reid JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191(2):217\u2013220. https:\/\/doi.org\/10.1016\/0014-2999(90)94150-v","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"3765_CR42","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1211\/0022357011777855","volume":"53","author":"M Forsling","year":"2001","unstructured":"Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (\u201cecstasy\u201d): is metabolism a contributory factor? J Pharm Pharmacol 53(10):1357\u20131363. https:\/\/doi.org\/10.1211\/0022357011777855","journal-title":"J Pharm Pharmacol"},{"issue":"3","key":"3765_CR43","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/sj.bjp.0704502","volume":"135","author":"ML Forsling","year":"2002","unstructured":"Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, \u2019ecstasy\u2019) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135(3):649\u2013656. https:\/\/doi.org\/10.1038\/sj.bjp.0704502","journal-title":"Br J Pharmacol"},{"issue":"2","key":"3765_CR44","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s00213-005-0149-6","volume":"183","author":"RR Freedman","year":"2005","unstructured":"Freedman RR, Johanson CE, Tancer ME (2005) Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 183(2):248\u2013256. https:\/\/doi.org\/10.1007\/s00213-005-0149-6","journal-title":"Psychopharmacology"},{"issue":"1","key":"3765_CR45","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.lfs.2013.07.023","volume":"97","author":"CL German","year":"2014","unstructured":"German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97(1):2\u20138. https:\/\/doi.org\/10.1016\/j.lfs.2013.07.023","journal-title":"Life Sci"},{"issue":"9","key":"3765_CR46","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/jnnp.56.9.1036","volume":"56","author":"JA Gledhill","year":"1993","unstructured":"Gledhill JA, Moore DF, Bell D, Henry JA (1993) Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psych 56(9):1036\u20131037. https:\/\/doi.org\/10.1136\/jnnp.56.9.1036","journal-title":"J Neurol Neurosurg Psych"},{"issue":"9","key":"3765_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002127","volume":"13","author":"S Golder","year":"2016","unstructured":"Golder S, Loke YK, Wright K, Norman G (2016) Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med 13(9):e1002127. https:\/\/doi.org\/10.1371\/journal.pmed.1002127","journal-title":"PLoS Med"},{"issue":"3","key":"3765_CR48","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1124\/pr.55.3.3","volume":"55","author":"AR Green","year":"2003","unstructured":"Green AR, Mechan AO, Elliott JM, O\u2019Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, \u201cecstasy\u201d). Pharmacol Rev 55(3):463\u2013508. https:\/\/doi.org\/10.1124\/pr.55.3.3","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3765_CR49","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","volume":"18","author":"G Greer","year":"1986","unstructured":"Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18(4):319\u2013327. https:\/\/doi.org\/10.1080\/02791072.1986.10472364","journal-title":"J Psychoactive Drugs"},{"key":"3765_CR50","first-page":"21","volume-title":"Ecstasy The Clinical Pharmacological and Neurotoxicological Effects of the Drug MDMA Topics in the Neurosciences","author":"GR Greer","year":"1990","unstructured":"Greer GR, Tolbert R (1990) The therapeutic use of MDMA. In: Peroutka SJ (ed) Ecstasy The Clinical Pharmacological and Neurotoxicological Effects of the Drug MDMA Topics in the Neurosciences. Springer, Boston, pp 21\u201335"},{"issue":"1","key":"3765_CR51","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0014-2999(93)90819-4","volume":"235","author":"XF Gu","year":"1993","unstructured":"Gu XF, Azmitia EC (1993) Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol 235(1):51\u201357. https:\/\/doi.org\/10.1016\/0014-2999(93)90819-4","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3765_CR52","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.tips.2018.11.001","volume":"40","author":"D Gulliver","year":"2019","unstructured":"Gulliver D, Werry E, Reekie TA, Katte TA, Jorgensen W, Kassiou M (2019) Targeting the oxytocin system: New pharmacotherapeutic approaches. Trends Pharmacol Sci 40(1):22\u201337. https:\/\/doi.org\/10.1016\/j.tips.2018.11.001","journal-title":"Trends Pharmacol Sci"},{"key":"3765_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugalcdep.2004.02.008","volume":"75","author":"JH Halpern","year":"2004","unstructured":"Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Todd D et al (2004) Residual neuropsychological effects of illicit 3,4- methelenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75:135\u2013147. https:\/\/doi.org\/10.1016\/j.drugalcdep.2004.02.008","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"3765_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2210-6-6","volume":"3","author":"DD Han","year":"2006","unstructured":"Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 3(6):6. https:\/\/doi.org\/10.1186\/1471-2210-6-6","journal-title":"BMC Pharmacol"},{"issue":"5","key":"3765_CR55","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1177\/003693309203700508","volume":"37","author":"DP Harries","year":"1992","unstructured":"Harries DP, De Silva R (1992) \u201cEcstasy\u201d and intracerebral haemorrhage. Scott Med J 37(5):150\u2013152. https:\/\/doi.org\/10.1177\/003693309203700508","journal-title":"Scott Med J"},{"key":"3765_CR56","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/0140-6736(92)91469-o","volume":"340","author":"JA Henry","year":"1992","unstructured":"Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxy- methamphetamine ('ecstasy\u2019). Lancet 340:384\u2013387. https:\/\/doi.org\/10.1016\/0140-6736(92)91469-o","journal-title":"Lancet"},{"issue":"10","key":"3765_CR57","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3109\/15563650.2014.976792","volume":"52","author":"F Heyerdahl","year":"2014","unstructured":"Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R, Wood DM, Dargan PI (2014) Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol (phila) 52(10):1005\u20131012. https:\/\/doi.org\/10.3109\/15563650.2014.976792","journal-title":"Clin Toxicol (phila)"},{"issue":"8","key":"3765_CR58","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3109\/15563650.2011.615318","volume":"49","author":"SL Hill","year":"2011","unstructured":"Hill SL, Thomas SH (2011) Clinical toxicology of newer recreational drugs. Clin Toxicol (phila) 49(8):705\u2013719. https:\/\/doi.org\/10.3109\/15563650.2011.615318. (Erratum in: Clin Toxicol (Phila) 49(9):880)","journal-title":"Clin Toxicol (phila)"},{"issue":"9007","key":"3765_CR59","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/s0140-6736(96)90196-8","volume":"347","author":"R Holden","year":"1996","unstructured":"Holden R, Jackson MA (1996) Near-fatal hyponatraemic coma due to vasopressin over-secretion after \u201cecstasy\u201d (3,4-MDMA). Lancet 347(9007):1052. https:\/\/doi.org\/10.1016\/s0140-6736(96)90196-8","journal-title":"Lancet"},{"key":"3765_CR60","unstructured":"Holland J (Ed.) (2001) Ecstasy: The complete guide: A comprehensive look at the risks and benefits of MDMA. Park Street Press"},{"key":"3765_CR61","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1136\/emj.10.4.372","volume":"10","author":"JC Hughes","year":"1993","unstructured":"Hughes JC, McCabe M, Evans RJ (1993) Intracranial haemorrhage associated with ingestion of \u201cecstasy.\u201d Arch Emerg Med 10:372\u2013374. https:\/\/doi.org\/10.1136\/emj.10.4.372","journal-title":"Arch Emerg Med"},{"key":"3765_CR62","doi-asserted-by":"publisher","first-page":"361","DOI":"10.5694\/j.1326-5377.2007.tb01282.x","volume":"187","author":"GK Isbister","year":"2007","unstructured":"Isbister GK, Buckley NA, Whyte IM (2007) Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 187:361\u2013365. https:\/\/doi.org\/10.5694\/j.1326-5377.2007.tb01282.x","journal-title":"Med J Aust"},{"issue":"8","key":"3765_CR63","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1007\/s00213-020-05548-2","volume":"237","author":"L Jerome","year":"2020","unstructured":"Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (2020) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237(8):2485\u20132497. https:\/\/doi.org\/10.1007\/s00213-020-05548-2","journal-title":"Psychopharmacology"},{"issue":"1","key":"3765_CR64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.jagp.2022.08.007","volume":"31","author":"CB Johnston","year":"2023","unstructured":"Johnston CB, Mangini M, Grob C, Anderson B (2023) The safety and efficacy of psychedelic-assisted therapies for older adults: Knowns and unknowns. Am J Geriatr Psychiatry 31(1):44\u201353. https:\/\/doi.org\/10.1016\/j.jagp.2022.08.007","journal-title":"Am J Geriatr Psychiatry"},{"issue":"3","key":"3765_CR65","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1046\/j.1365-2826.2003.00978.x","volume":"15","author":"H J\u00f8rgensen","year":"2003","unstructured":"J\u00f8rgensen H, Riis M, Knigge U, Kjaer A, Warberg J (2003) Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 15(3):242\u2013249. https:\/\/doi.org\/10.1046\/j.1365-2826.2003.00978.x","journal-title":"J Neuroendocrinol"},{"issue":"7","key":"3765_CR66","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1038\/npp.2014.12","volume":"2039","author":"MG Kirkpatrick","year":"2014","unstructured":"Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H (2014) Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology 2039(7):1654\u20131663. https:\/\/doi.org\/10.1038\/npp.2014.12","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"3765_CR67","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/JCP.0b013e31817ef470","volume":"28","author":"EA Kolbrich","year":"2008","unstructured":"Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28(4):432\u2013440. https:\/\/doi.org\/10.1097\/JCP.0b013e31817ef470","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"3765_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100719","volume":"9","author":"KP Kuypers","year":"2014","unstructured":"Kuypers KP, de la Torre R, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos W, Ramaekers JG (2014) No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS ONE 9(6):e100719. https:\/\/doi.org\/10.1371\/journal.pone.0100719","journal-title":"PLoS ONE"},{"issue":"2","key":"3765_CR69","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00213-017-4699-1.Erratum.In:Psychopharmacology(Berl)2017Aug1;PMID:28735368;PMCID:PMC5813067","volume":"235","author":"KPC Kuypers","year":"2018","unstructured":"Kuypers KPC, de la Torre R, Farre M, Pizarro N, Xicota L, Ramaekers JG (2018) MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor. Psychopharmacology 235(2):481\u2013490. https:\/\/doi.org\/10.1007\/s00213-017-4699-1.Erratum.In:Psychopharmacology(Berl)2017Aug1;PMID:28735368;PMCID:PMC5813067","journal-title":"Psychopharmacology"},{"issue":"4","key":"3765_CR70","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/npp.1994.26","volume":"10","author":"ET Leonardi","year":"1994","unstructured":"Leonardi ET, Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10(4):231\u2013238. https:\/\/doi.org\/10.1038\/npp.1994.26","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"3765_CR71","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1681\/ASN.2007010029","volume":"19","author":"C Li","year":"2008","unstructured":"Li C, Wang W, Summer SN, Westfall TD, Brooks DP, Falk S, Schrier RW (2008) Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol 19(2):225\u2013232. https:\/\/doi.org\/10.1681\/ASN.2007010029","journal-title":"J Am Soc Nephrol"},{"key":"3765_CR72","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2015.14043","volume":"145","author":"M Liechti","year":"2015","unstructured":"Liechti M (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 145:w14043. https:\/\/doi.org\/10.4414\/smw.2015.14043","journal-title":"Swiss Med Wkly"},{"issue":"4","key":"3765_CR73","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/S0893-133X(00)00126-3","volume":"23","author":"ME Liechti","year":"2000","unstructured":"Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000) Psychological and physiological effects of MDMA (\u201cEcstasy\u201d) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23(4):396\u2013404. https:\/\/doi.org\/10.1016\/S0893-133X(00)00126-3","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"3765_CR74","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1097\/00005053-199206000-00001","volume":"180","author":"MB Liester","year":"1992","unstructured":"Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 180(6):345\u2013352. https:\/\/doi.org\/10.1097\/00005053-199206000-00001","journal-title":"J Nerv Ment Dis"},{"issue":"8","key":"3765_CR75","first-page":"205S","volume":"53","author":"S Ludewig","year":"2003","unstructured":"Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in healthy humans. Biol Psychiatry 53(8):205S","journal-title":"Biol Psychiatry"},{"key":"3765_CR500","unstructured":"Lykos Therapeutics announces FDA acceptance and Priority Review of New Drug application for MDMA-assisted therapy for PTSD. Available from https:\/\/news.lykospbc.com\/2024-02-09-Lykos-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-MDMA-Assisted-Therapy-for-PTSD. Accessed 5 May 2024"},{"issue":"12","key":"3765_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.824288","volume":"24","author":"T Makunts","year":"2022","unstructured":"Makunts T, Jerome L, Abagyan R, de Boer A (2022) Reported cases of serotonin syndrome in MDMA users in FAERS database. Front Psychiatry 24(12):824288. https:\/\/doi.org\/10.3389\/fpsyt.2021.824288","journal-title":"Front Psychiatry"},{"issue":"817","key":"3765_CR77","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/pgmj.69.817.874","volume":"69","author":"S Manchanda","year":"1993","unstructured":"Manchanda S, Connolly MJ (1993) Cerebral infarction in association with Ecstasy abuse. Postgrad Med J 69(817):874\u2013875. https:\/\/doi.org\/10.1136\/pgmj.69.817.874","journal-title":"Postgrad Med J"},{"issue":"3","key":"3765_CR78","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/02698811211069124","volume":"36","author":"JL Maples-Keller","year":"2022","unstructured":"Maples-Keller JL, Norrholm SD, Burton M et al (2022) A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol 36(3):368\u2013377. https:\/\/doi.org\/10.1177\/02698811211069124","journal-title":"J Psychopharmacol"},{"key":"3765_CR79","unstructured":"MAPS Public Benefit Corporation Investigator\u2019s brochure (2023) Available at https:\/\/maps.org\/wp-content\/uploads\/2023\/04\/MDMA-IB-15th-Edition_FINAL_13MAR2023_MRC.pdf (Accessed Sept 20, 2023)"},{"key":"3765_CR80","first-page":"136","volume":"290","author":"M Mas","year":"1999","unstructured":"Mas M, Farre M, de la Torre R, Roset PN, Ortu\u00f1o J, Segura J et al (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136\u2013145","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"3765_CR81","doi-asserted-by":"publisher","first-page":"107","DOI":"10.2165\/00002018-199615020-00003","volume":"15","author":"UD McCann","year":"1996","unstructured":"McCann UD, Slate SO, Ricaurte GA (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; \u2019ecstasy\u2019). Drug Saf 15(2):107\u2013115. https:\/\/doi.org\/10.2165\/00002018-199615020-00003","journal-title":"Drug Saf"},{"issue":"6","key":"3765_CR82","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","volume":"27","author":"JM Mitchell","year":"2021","unstructured":"Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K et al (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27(6):1025\u20131033. https:\/\/doi.org\/10.1038\/s41591-021-01336-3","journal-title":"Nat Med"},{"issue":"10","key":"3765_CR83","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","volume":"29","author":"JM Mitchell","year":"2023","unstructured":"Mitchell JM, Ot\u2019alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y et al (2023) MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29(10):2473\u20132480. https:\/\/doi.org\/10.1038\/s41591-023-02565-4","journal-title":"Nat Med"},{"key":"3765_CR84","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1177\/0269881110378371","volume":"25","author":"MC Mithoefer","year":"2011","unstructured":"Mithoefer MC, Wagner TM, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of \u00b13,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439\u2013452. https:\/\/doi.org\/10.1177\/0269881110378371","journal-title":"J Psychopharmacol"},{"key":"3765_CR85","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0269881112456611","volume":"27","author":"MC Mithoefer","year":"2013","unstructured":"Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B et al (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependence after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow- up study. J Psychopharmacol 27:28\u201339. https:\/\/doi.org\/10.1177\/0269881112456611","journal-title":"J Psychopharmacol"},{"key":"3765_CR86","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","volume":"5","author":"MC Mithoefer","year":"2018","unstructured":"Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J et al (2018) 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486\u2013497. https:\/\/doi.org\/10.1016\/S2215-0366(18)30135-4","journal-title":"Lancet Psychiatry"},{"key":"3765_CR87","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","volume":"236","author":"MC Mithoefer","year":"2019","unstructured":"Mithoefer MC, Jerome L, Mithoefer A, Wagner M, Walsh Z et al (2019) MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236:2735\u20132745. https:\/\/doi.org\/10.1007\/s00213-019-05249-5","journal-title":"Psychopharmacology"},{"key":"3765_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.290.6462.113","author":"FT Mwambingu","year":"1985","unstructured":"Mwambingu FT (1985) Water intoxication and oxytocin. Br Med J (clin Res Ed). https:\/\/doi.org\/10.1136\/bmj.290.6462.113","journal-title":"Br Med J (clin Res Ed)"},{"issue":"7754","key":"3765_CR89","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41586-019-1075-9","volume":"569","author":"R Nardou","year":"2019","unstructured":"Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, D\u00f6len G (2019) Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature 569(7754):116\u2013120. https:\/\/doi.org\/10.1038\/s41586-019-1075-9","journal-title":"Nature"},{"issue":"4","key":"3765_CR90","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.1986.10472362","volume":"18","author":"DE Nichols","year":"1986","unstructured":"Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class: entactogens. J Psychoact Drugs 18(4):305\u2013313. https:\/\/doi.org\/10.1080\/02791072.1986.10472362","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"3765_CR91","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478.Erratum.In:PharmacolRev68(2):356","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478.Erratum.In:PharmacolRev68(2):356","journal-title":"Pharmacol Rev"},{"key":"3765_CR92","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.863088","volume":"13","author":"DE Nichols","year":"2022","unstructured":"Nichols DE (2022) Entactogens: how the name for a novel class of psychoactive agents originated. Front Psychiatry 13:863088. https:\/\/doi.org\/10.3389\/fpsyt.2022.863088","journal-title":"Front Psychiatry"},{"issue":"2","key":"3765_CR93","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/cpt.557","volume":"101","author":"DE Nichols","year":"2017","unstructured":"Nichols DE, Johnson MW, Nichols CD (2017) Psychedelics as medicines: An emerging new paradigm. Clin Pharmacol Ther 101(2):209\u2013219. https:\/\/doi.org\/10.1002\/cpt.557","journal-title":"Clin Pharmacol Ther"},{"key":"3765_CR94","unstructured":"NIDA (2022) What is MDMA?. National Institute on Drug Abuse website. https:\/\/nida.nih.gov\/publications\/research-reports\/mdma-ecstasy-abuse\/what-mdma. Dec 19, 2022. Accessed Febr 19, 2024"},{"key":"3765_CR95","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/nrn3530","volume":"14","author":"DJ Nutt","year":"2013","unstructured":"Nutt DJ, King LA, Nichols DE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14:577\u2013585. https:\/\/doi.org\/10.1038\/nrn3530","journal-title":"Nat Rev Neurosci"},{"key":"3765_CR96","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1177\/0269881112464827","volume":"27","author":"P Oehen","year":"2013","unstructured":"Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 27:40\u201352. https:\/\/doi.org\/10.1177\/0269881112464827","journal-title":"J Psychopharmacol"},{"issue":"5","key":"3765_CR97","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/0269881120920420","volume":"35","author":"HE Oeri","year":"2021","unstructured":"Oeri HE (2021) Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol 35(5):512\u2013536. https:\/\/doi.org\/10.1177\/0269881120920420","journal-title":"J Psychopharmacol"},{"key":"3765_CR98","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1177\/0269881118806297","volume":"32","author":"G Ota'lora","year":"2018","unstructured":"Ota\u2019lora G, Grigsby J, Poulter B, Van Derveer JW, III, Giron SG, Jerome L, et al (2018) MDMA-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized controlled trial. J Psychopharmacol 32:1295\u20131307. https:\/\/doi.org\/10.1177\/0269881118806297","journal-title":"J Psychopharmacol"},{"issue":"3","key":"3765_CR99","doi-asserted-by":"publisher","first-page":"136","DOI":"10.5694\/j.1326-5377.1997.tb140044.x","volume":"166","author":"MJ Parr","year":"1997","unstructured":"Parr MJ, Low HM, Botterill P (1997) Hyponatraemia and death after \u201cecstasy\u201d ingestion. Med J Aust 166(3):136\u2013137. https:\/\/doi.org\/10.5694\/j.1326-5377.1997.tb140044.x","journal-title":"Med J Aust"},{"issue":"1","key":"3765_CR100","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/jpet.106.103622","volume":"319","author":"JS Partilla","year":"2006","unstructured":"Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319(1):237\u2013246. https:\/\/doi.org\/10.1124\/jpet.106.103622","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"3765_CR101","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/02791072.2001.10400568","volume":"33","author":"AR Pentney","year":"2001","unstructured":"Pentney AR (2001) An exploration of the history and controversies surrounding MDMA and MDA. J Psychoactive Drugs 33(3):213\u2013221. https:\/\/doi.org\/10.1080\/02791072.2001.10400568","journal-title":"J Psychoactive Drugs"},{"issue":"4","key":"3765_CR102","first-page":"273","volume":"1","author":"SJ Peroutka","year":"1988","unstructured":"Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1(4):273\u2013277","journal-title":"Neuropsychopharmacology"},{"key":"3765_CR103","unstructured":"Peryer G, Golder S, Junqueira D, et al (2021) Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (Updated Febr 2021). Cochrane. Available at: http:\/\/www.training.cochrane.org\/handbook (accessed 21 October 2023)."},{"key":"3765_CR104","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s12954-021-00489-1","volume":"18","author":"B Pilecki","year":"2021","unstructured":"Pilecki B, Luoma JB, Bathje GJ et al (2021) Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J 18:40. https:\/\/doi.org\/10.1186\/s12954-021-00489-1","journal-title":"Harm Reduct J"},{"issue":"1\u20133","key":"3765_CR105","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.forsciint.2011.04.008","volume":"215","author":"JL Pilgrim","year":"2012","unstructured":"Pilgrim JL, Gerostamoulos D, Woodford N, Drummer OH (2012) Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int 215(1\u20133):184\u2013188. https:\/\/doi.org\/10.1016\/j.forsciint.2011.04.008","journal-title":"Forensic Sci Int"},{"key":"3765_CR106","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3389\/fpsyt.2019.00881","volume":"10","author":"KH Preller","year":"2019","unstructured":"Preller KH, Vollenweider FX (2019) Modulation of social cognition via hallucinogens and \u201cEntactogens.\u201d Front Psychiatry 10:881. https:\/\/doi.org\/10.3389\/fpsyt.2019.00881","journal-title":"Front Psychiatry"},{"key":"3765_CR107","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-011-0193-z","author":"JM Prosser","year":"2011","unstructured":"Prosser JM, Nelson LS (2011) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. https:\/\/doi.org\/10.1007\/s13181-011-0193-z","journal-title":"J Med Toxicol"},{"issue":"2","key":"3765_CR108","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0301-0082(91)90020-2","volume":"36","author":"LP Renaud","year":"1991","unstructured":"Renaud LP, Bourque CW (1991) Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Prog Neurobiol 36(2):131\u2013169. https:\/\/doi.org\/10.1016\/0301-0082(91)90020-2","journal-title":"Prog Neurobiol"},{"key":"3765_CR109","unstructured":"Report to the Therapeutic Goods Administration (2023) Available at: https:\/\/www.tga.gov.au\/sites\/default\/files\/mmda-and-psilocybin-independent-expert-panel-review-final-report.pdf (Accessed Oct 3 2023)"},{"issue":"13","key":"3765_CR110","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1111\/bph.13128","volume":"172","author":"A Rickli","year":"2015","unstructured":"Rickli A, Kopf S, Hoener MC, Liechti ME (2015) Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol 172(13):3412\u20133425. https:\/\/doi.org\/10.1111\/bph.13128","journal-title":"Br J Pharmacol"},{"issue":"4","key":"3765_CR111","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3390\/jpm10040198","volume":"10","author":"V Rollason","year":"2020","unstructured":"Rollason V, Lloret-Linares C, Lorenzini KI, Daali Y, Gex-Fabry M, Piguet V et al (2020) Evaluation of phenotypic and genotypic variations of drug metabolising enzymes and transporters in chronic pain patients facing adverse drug reactions or non-response to analgesics: a retrospective study. J Pers Med 10(4):198. https:\/\/doi.org\/10.3390\/jpm10040198","journal-title":"J Pers Med"},{"issue":"1\u20133","key":"3765_CR112","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejphar.2003.08.054","volume":"479","author":"RB Rothman","year":"2003","unstructured":"Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479(1\u20133):23\u201340. https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.054","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"3765_CR113","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/jnnp.56.9.1035","volume":"56","author":"PM Rothwell","year":"1993","unstructured":"Rothwell PM, Grant R (1993) Cerebral venous sinus thrombosis induced by \u201cecstasy.\u201d J Neurol Neurosurg Psychiatry 56(9):1035\u20131039. https:\/\/doi.org\/10.1136\/jnnp.56.9.1035","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3765_CR114","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.102630","volume":"76","author":"A Roxburgh","year":"2020","unstructured":"Roxburgh A, Lappin J (2020) MDMA-related deaths in Australia 2000 to 2018. Int J Drug Policy 76:102630. https:\/\/doi.org\/10.1016\/j.drugpo.2019.102630","journal-title":"Int J Drug Policy"},{"key":"3765_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2021.113778","volume":"343","author":"D Rudin","year":"2021","unstructured":"Rudin D, Liechti ME, Luethi D (2021) Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Exp Neurol 343:113778. https:\/\/doi.org\/10.1016\/j.expneurol.2021.113778","journal-title":"Exp Neurol"},{"issue":"5","key":"3765_CR116","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1073\/pnas.89.5.1817","volume":"89","author":"G Rudnick","year":"1992","unstructured":"Rudnick G, Wall SC (1992) The molecular mechanism of \u201cecstasy\u201d [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89(5):1817\u20131821. https:\/\/doi.org\/10.1073\/pnas.89.5.1817","journal-title":"Proc Natl Acad Sci USA"},{"key":"3765_CR117","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1136\/bmj.326.7380.80","volume":"326","author":"F Schifano","year":"2003","unstructured":"Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003) Review of deaths related to taking ecstasy, England and Wales, 1997\u20132000. BMJ 326:80\u201381. https:\/\/doi.org\/10.1136\/bmj.326.7380.80","journal-title":"BMJ"},{"key":"3765_CR118","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000279302","volume":"61","author":"F Schifano","year":"2010","unstructured":"Schifano F, Corkery J, Naidoo V, Oyefeso A, Ghodse H (2010) Overview of amphetamine-type stimulant mortality data\u2014UK, 1997\u20132007. Neuropsychobiology 61:122\u2013130. https:\/\/doi.org\/10.1159\/000279302","journal-title":"Neuropsychobiology"},{"issue":"1","key":"3765_CR119","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1017\/S0033291719001727","volume":"51","author":"F Schifano","year":"2021","unstructured":"Schifano F, Napoletano F, Chiappini S, Guirguis A, Corkery J, Bonaccorso S et al (2021) New\/emerging psychoactive substances and associated psychopathological consequences. Psychol Med 51(1):30\u201342. https:\/\/doi.org\/10.1017\/S0033291719001727","journal-title":"Psychol Med"},{"issue":"4","key":"3765_CR120","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s00213-009-1688-z","volume":"207","author":"T Schilt","year":"2010","unstructured":"Schilt T, Koeter MW, Smal JP, Gouwetor MN, van den Brink W, Schmand B (2010) Long-term neuropsychological effects of ecstasy in middle-aged ecstasy\/polydrug users. Psychopharmacology 207(4):583\u2013591. https:\/\/doi.org\/10.1007\/s00213-009-1688-z","journal-title":"Psychopharmacology"},{"issue":"8794","key":"3765_CR121","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/0140-6736(92)90834-p","volume":"339","author":"GR Screaton","year":"1992","unstructured":"Screaton GR, Cairns HS, Samer M et al (1992) Hyperpyrexia and rhabdomyolysis after MDMA ('ecstasy\u2019) abuse. Lancet 339(8794):677\u2013678. https:\/\/doi.org\/10.1016\/0140-6736(92)90834-p","journal-title":"Lancet"},{"key":"3765_CR122","first-page":"87","volume-title":"Breaking Convention Book of Proceedings from the 2013 Conference","author":"B Sessa","year":"2015","unstructured":"Sessa B (2015) The ecstatic history of MDMA: from raving highs to saving lives. Breaking Convention Book of Proceedings from the 2013 Conference. Strange Attractor Press, London, pp 87\u201394"},{"key":"3765_CR123","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3389\/fpsyt.2019.00138","volume":"10","author":"B Sessa","year":"2019","unstructured":"Sessa B, Higbed L, Nutt D (2019) A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychopharmacology 10:138. https:\/\/doi.org\/10.3389\/fpsyt.2019.00138","journal-title":"Front Psychopharmacology"},{"key":"3765_CR124","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1177\/0269881121991792","volume":"35","author":"B Sessa","year":"2021","unstructured":"Sessa B, Higbed L, O\u2019Brien S, Durant C, Sakal C, Titheradge D et al (2021) First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol 35:375\u2013383. https:\/\/doi.org\/10.1177\/0269881121991792","journal-title":"J Psychopharmacol"},{"issue":"4","key":"3765_CR125","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/02791072.1986.10472361","volume":"18","author":"AT Shulgin","year":"1986","unstructured":"Shulgin AT (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18(4):291\u2013304. https:\/\/doi.org\/10.1080\/02791072.1986.10472361","journal-title":"J Psychoactive Drugs"},{"key":"3765_CR126","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1476-5381.2012.02145.x","volume":"168","author":"L Simmler","year":"2013","unstructured":"Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J et al (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458\u2013470. https:\/\/doi.org\/10.1111\/j.1476-5381.2012.02145.x","journal-title":"Br J Pharmacol"},{"key":"3765_CR127","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neuropharm.2013.11.008","volume":"79","author":"LD Simmler","year":"2014","unstructured":"Simmler LD, Rickli A, Hoener MC, Liechti ME (2014a) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152\u2013160. https:\/\/doi.org\/10.1016\/j.neuropharm.2013.11.008","journal-title":"Neuropharmacology"},{"key":"3765_CR128","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.bcp.2014.01.024","volume":"88","author":"LD Simmler","year":"2014","unstructured":"Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014b) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88:237\u2013244. https:\/\/doi.org\/10.1016\/j.bcp.2014.01.024","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"3765_CR129","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/j.1360-0443.1992.tb02003.x","volume":"87","author":"N Solowij","year":"1992","unstructured":"Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of \u201cEcstacy\u201d users and their experiences with the drug. Br J Addict 87(8):1161\u20131172. https:\/\/doi.org\/10.1111\/j.1360-0443.1992.tb02003.x","journal-title":"Br J Addict"},{"key":"3765_CR130","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1001\/jama.2015.8370","volume":"314","author":"MM Steenkamp","year":"2015","unstructured":"Steenkamp MM, Litz B, Hoge CW, Marmar CR (2015) Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA 314:489\u2013500. https:\/\/doi.org\/10.1001\/jama.2015.8370","journal-title":"JAMA"},{"key":"3765_CR131","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1097\/00000433-198812000-00015","volume":"9","author":"RV Suarez","year":"1988","unstructured":"Suarez RV, Riemersma R (1988) \u201cEcstasy\u201d and sudden cardiac death. Am J Forensic Med Pathol 9:339\u2013341. https:\/\/doi.org\/10.1097\/00000433-198812000-00015","journal-title":"Am J Forensic Med Pathol"},{"key":"3765_CR132","unstructured":"TGA classification of psilocybin and MDMA (2023) Available at: https:\/\/www.tga.gov.au\/news\/media-releases\/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists (Accessed Sept 20 2023)."},{"issue":"2","key":"3765_CR133","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neuroscience.2007.02.032","volume":"146","author":"MR Thompson","year":"2007","unstructured":"Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (\u201cecstasy\u201d). Neuroscience 146(2):509\u2013514. https:\/\/doi.org\/10.1016\/j.neuroscience.2007.02.032","journal-title":"Neuroscience"},{"key":"3765_CR134","unstructured":"Tolerability of MDMA in Schizophrenia (TMS) (2023) Available at: https:\/\/clinicaltrials.gov\/study\/NCT05770375. (Accessed Oct 3, 2023)"},{"key":"3765_CR135","unstructured":"Topp L, Hall W, Hando J (1997) Is there a dependence syndrome for ecstasy? NDARC Technical Report No. 51. Available at: https:\/\/ndarc.med.unsw.edu.au\/sites\/default\/files\/ndarc\/resources\/TR.051.pdf. (Accessed April 4, 2024)"},{"key":"3765_CR136","unstructured":"UNODC early warning advisory on new psychoactive substances (2023) https:\/\/www.unodc.org\/LSS\/Page\/NPS; UNDOC Current NPS threats Vol VI August 2023 https:\/\/www.unodc.org\/res\/scientists\/ewa\/Current_NPS_Threats_VI.pdf) (Accessed Sept 3, 2023)."},{"issue":"7","key":"3765_CR137","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040187","volume":"7","author":"JH van Wel","year":"2012","unstructured":"van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG (2012) Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS ONE 7(7):e40187. https:\/\/doi.org\/10.1371\/journal.pone.0040187","journal-title":"PLoS ONE"},{"issue":"4","key":"3765_CR138","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00213-005-0174-5","volume":"189","author":"CD Verrico","year":"2007","unstructured":"Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4):489\u2013503. https:\/\/doi.org\/10.1007\/s00213-005-0174-5","journal-title":"Psychopharmacology"},{"key":"3765_CR139","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/0269881117691569","volume":"31","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31:576\u2013588. https:\/\/doi.org\/10.1177\/0269881117691569","journal-title":"J Psychopharmacol"},{"issue":"3","key":"3765_CR140","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.euroneuro.2017.01.008","volume":"27","author":"P Vizeli","year":"2017","unstructured":"Vizeli P, Schmid Y, Prestin K, Schwabedissen MZ, HE, Liechti ME, (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharmacol 27(3):232\u2013238. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.01.008","journal-title":"Eur Neuropsychopharmacol"},{"issue":"4","key":"3765_CR141","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0893-133X(98)00013-X","volume":"19","author":"FX Vollenweider","year":"1998","unstructured":"Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (\u201cecstasy\u201d) in MDMA-na\u00efve healthy volunteers. Neuropsychopharmacology 19(4):241\u2013251. https:\/\/doi.org\/10.1016\/S0893-133X(98)00013-X","journal-title":"Neuropsychopharmacology"},{"key":"3765_CR142","first-page":"476","volume":"51","author":"T Walsh","year":"1994","unstructured":"Walsh T, Carmichael R, Chestnut R (1994) A hyperthermic reaction to \u201cecstasy.\u201d Br J Hosp Med 51:476","journal-title":"Br J Hosp Med"},{"key":"3765_CR143","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/da.1029","volume":"13","author":"FW Weathers","year":"2001","unstructured":"Weathers FW, Keane TM, Davidson JR (2001) Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 13:132\u2013156. https:\/\/doi.org\/10.1002\/da.1029","journal-title":"Depress Anxiety"},{"issue":"1","key":"3765_CR144","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/09595230500124925","volume":"24","author":"P Williams","year":"2005","unstructured":"Williams P (2005) Correlates of ecstasy use in middle age and beyond. Drug Alcohol Rev 24(1):33\u201338. https:\/\/doi.org\/10.1080\/09595230500124925","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"3765_CR145","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1177\/0269881106061514","volume":"20","author":"K Wolff","year":"2006","unstructured":"Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison K (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 20(3):400\u2013410. https:\/\/doi.org\/10.1177\/0269881106061514","journal-title":"J Psychopharmacol"},{"issue":"1","key":"3765_CR146","doi-asserted-by":"publisher","first-page":"20442","DOI":"10.1038\/s41598-020-75706-1","volume":"10","author":"PE Wolfson","year":"2020","unstructured":"Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E et al (2020) MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep 10(1):20442. https:\/\/doi.org\/10.1038\/s41598-020-75706-1","journal-title":"Sci Rep"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03765-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03765-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03765-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T07:05:18Z","timestamp":1721891118000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03765-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":147,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3765"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03765-8","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"19 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no known competing financial interests or personal relationships that influenced the work reported here.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}